There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
TAK-375 (Ramelteon), a melatonin ML1/MT1 receptor agonist for the potential treatment of primary insomnia, is being developed by Takeda. Takeda submitted an NDA to the FDA for TAK-375 in September 2004.